DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for mucocutaneous lymph node syndrome — screening already-approved drugs against its 15-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMucocutaneous lymph node syndrome maps to a 15-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for mucocutaneous lymph node syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
MIA SH3 domain containing (MIA) — MIA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet lgadrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5IXB · 1.39 Å · ligand PYRIMIDIN-2-AMINE (LGA). Experimental structure, not a prediction.
What the evidence adds up to
Mucocutaneous lymph node syndrome, also called Kawasaki disease, was first described in Japanese children and by the late 1970s was being reported in the United States and Korea. Three adults aged 16 to 27 years were reported in 1979 with findings compatible with the illness, which had previously been thought to occur only in children. The syndrome involves cervical lymph nodes, skin, and mucous membranes, and presents with fever, polymorphous skin eruption, congested conjunctiva, reddened palms and soles, red lips and oral mucous membrane, and soft-tissue swelling of the peripheral extremities, followed by membranous desquamation of fingers and toes. No laboratory test was available in 1979 to confirm the diagnosis.
In a series of 15 infants and children treated at Louisiana State University teaching hospitals between August 1978 and January 1981, the male to female ratio was 2:1, and 53% of patients were between 11 and 15 months of age. A cluster of nine cases (60%) occurred between February and May 1980. In five of these patients, platelet counts and erythrocyte sedimentation rates were monitored for at least four weeks. The course is usually benign and self-limiting, but a number of deaths have resulted from coronary artery disease.
Nearly 7,000 cases of mucocutaneous lymph node syndrome had been reported in Japan since 1970, and eight cases had been described in Korea in 1973. The claim that the syndrome had not been reported outside Japan and Hawaii was incorrect.
What is still missing is any controlled trial of treatment for the syndrome in adults or children, any validated diagnostic laboratory test, and any reliable method to identify which patients will develop coronary artery complications. The abstracts provide no data on response rates, survival, or drug efficacy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
JAMA · 1979 · 67 citations
Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) in Adults
AbstractMucocutaneous lymph node syndrome has been reported to occur only in children. Three adults aged 16 to 27 years had findings compatible with this illness. Patients with fever, polymorphous skin eruption, congested conjunctiva, reddened palms and soles, red lips and oral mucous membrane, and soft-tissue swelling of the peripheral extremities and who experience membranous desquamation of fingers and toes should be suspected of having mucocutaneous lymph node syndrome. No laboratory test is currently available for confirmation of the diagnosis.
AbstractMucocutaneous lymph node syndrome represents a series of clinical findings that has been observed primarily in Japanese children. The disease now appears to be migrating to this country. It involves the cervical lymph nodes, the skin, and mucus membranes. Although the course is usually benign and self-limiting, a number of deaths have resulted from coronary artery disease.
Mucocutaneous Lymph Node Syndrome in North Louisiana
AbstractMucocutaneous lymph node syndrome (MLNS) is being more frequently reported in the United States, and it appears to be an important disease of childhood. Fifteen infants and children with MLNS were treated at the Louisiana State University teaching hospitals in Shreveport and Monroe between August 1978 and January 1981. A cluster of nine of the cases (60%) occurred between February and May 1980. In this series the male to female ratio was 2:1, and 53% of the patients were between 11 and 15 months of age. In five of the patients, platelet counts and erythrocyte sedimentation rates were monitored for at least four weeks.
Asian Pacific Journal of Cancer Prevention · 2012 · 1 citations · open access
Neck Node Bolus Technique in the Treatment of Nasopharyngeal Carcinoma with Intensity-modulated Radiotherapy
AbstractPURPOSE: To study the effect of bolus versus no bolus in the coverage of the nodal tumour volume with intensity-modulated radiotherapy (IMRT) for the treatment of nasopharyngeal carcinoma (NPC). METHODS AND MATERIALS: This retrospective study used data from 5 consecutive patients with NPC who were treated with bolus for large neck nodes using IMRT from November 2011-January 2012 in our institute. All these patients were treated radically with IMRT according to our institution's protocol. Re-planning with IMRT without bolus for these patients with exactly the same target volumes were done for comparison. Comparison of the plans was done by comparing the V70 of PTV70-N, V66.5 of PTV70-N, V65.1 of PTV70-N and the surface dose of the PTV70-N. RESULTS: The mean size of the largest diameter of the enlarged lymph nodes for the 5 patients was 3.9 cm. The mean distance of the GTV-N to the skin surface was 0.6 cm. The mean V70 of PTV70-N for the 5 patients showed an absolute advantage of 10.8% (92.4% vs. 81.6%) for the plan with bolus while the V66.5 of PTV70-N had an advantage of 8.1% (97.0% vs. 88.9%). The mean V65.1 also had an advantage of 7.1% (97.6% vs. 90.5%). The mean surface dose for the PTV70-N was also much higher at 61.1 Gy for the plans with bolus compared to only 23.5 Gy for the plans without bolus. CONCLUSION: Neck node bolus technique should be strongly considered in the treatment of NPC with enlarged lymph nodes treated with IMRT. It yields a superior dosimetry compared to non-bolus plans with acceptable skin toxicity.
Geographic Prevalence of Mucocutaneous Lymph Node Syndrome
AbstractIn the March 1976 issue of Pediatrics (57:431, 1976), Goldsmith et al. reported a case of mucocutaneous lymph node syndrome (MLNS) in New Jersey. They stated that this syndrome has not been reported from any area other than Japan and Hawaii. This is incorrect, as eight cases of MLNS had been described in Korea in 1973.1 These cases were referred to in an article by Kato et al.,2 which was cited by Goldsmith et al. Nearly 7,000 cases of MLNS have been reported in Japan since 1970,2 and not 4,000 since 1967 as stated by Goldsmith et al.
Chinese journal of plastic surgery · 2018 · 0 citations
Recent progress in the vascularized lymph node transfer for the treatment of lymphedema
AbstractThe lymphedema is the most common cause of the refractory extremity thickness, which severely affects the quality of patients′ life and is also an intractable issue for therapy. Among the surgical therapies currently being practiced for lymphedema, free vascularized lymph nodes transfer(VLNT) is a promising option. The purpose of this review is to summarize specific issues of VLNT with regard to the mechanism, the surgical technique, agents application, postoperative care and outcomes.
Key words:
Lymphedema; Vascularized lymph nodes transfer
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
